NUT Carcinoma of the Sublingual Gland

Head and Neck Pathology

Volumn 10, Issue 3, 2016, Pages 362-366

  Andreasen, S ^a,b,c   French, C A ^d   Josiassen, M ^a   Hahn, C H ^a   Kiss, K ^a  

^a Rigshospitalet   (Denmark)

^b Køge University Hospital   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRD4 NUT; Carcinoma; Fusion protein; NUT; Salivary gland; Sublingual gland

Indexed keywords

BRD4-NUT FUSION ONCOGENE PROTEIN, HUMAN; NUCLEAR PROTEIN; NUT PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADULT; CASE REPORT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGY; SALIVARY GLAND TUMOR; SQUAMOUS CELL CARCINOMA;

ADULT; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; SUBLINGUAL GLAND NEOPLASMS;

EID: 84947593837     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-015-0672-7     Document Type: Article

References (18)

1. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol Mech Dis. 2012;7:247–65.
2. French CA, Miyoshi I, Kubonishi I, et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304–7.
3. French CA, Ramirez CL, Kolmakova J, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27:2237–42.
4. French CA, den Bakker M. NUT carcinoma. In: Travis W, Brambilla E, Müller-Hermelink H, Harris C, editors. World health organization classification of tumours of lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2015. p. 229–31.
5. French CA, Kutok JL, Faquin WC, et al. Midline carcinoma of children and young adults with NUT rearrangement. J Clin Oncol. 2004;22:4135–9.
6. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773–9.
7. Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32:828–34.
8. Stelow EB. A review of NUT midline carcinoma. Head Neck Pathol. 2011;5:31–5.
9. Ziai J, French CA, Zambrano E. NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland. Head Neck Pathol. 2010;4:163–8.
10. den Bakker MA, Beverloo BH, van den Heuvel-Eibrink MM, et al. NUT midline carcinoma of the parotid gland with mesenchymal differentiation. Am J Surg Pathol. 2009;33:1253–8.
11. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 79–86.
12. French CA, Rahman S, Walsh EM, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discov. 2014;4:928–41.
13. Tsang WYW, Kuo TT, Chan JKC. Lymphoepithelial carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health organization classification of tumours pathology & genetics head and neck tumours. Lyon: IARC press; 2005. p. 251–2.
14. Nagao T, Sugano I, Ishida Y, et al. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases. Mod Pathol. 2000;13:554–61.
15. Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33:984–91.
16. Fang W, French CA, Cameron MJ, et al. Clinicopathological significance of NUT rearrangements in poorly differentiated malignant tumors of the upper respiratory tract. Int J Surg Pathol. 2012;21:102–10.
17. Stenman G, Persson F, Andersson MK. Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol. 2014;50:683–90.
18. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067–73.